| Pfisterer M et al, Switzerland, 1998 | Patients with acute MI | Prospectively planned post hoc analyses of the GUSTO-I dataset (a multicentre PRCT) | Mortality any atenolol v none | 30 day mortality was significantly lower in atenolol treated patients. | |
| No atenolol (n=10 073) vs any atenolol (n=30 771) | | Mortality IV atenolol vs oral | More likely to die (odds ratio 1.3 (95% CI 1, 1.5) p=0.02) | |
| Any intravenous atenolol (n=18 200)vs oral atenolol only (n=12 545) v both intravenous and oral drug (n=16 406) | | Morbidity | More heart failure, shock, recurrent ischaemia and pacemaker use | |